Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006

Inflammatory Bowel Diseases

Volumn 13, Issue 8, 2007, Pages 1031-1050

  Latella, Giovanni ^a   Fiocchi, Claudio ^b   Caprilli, Renzo ^c,d  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Genetics; Immunomodulation; Inflammatory bowel diseases; Intestinal microflora; Novel therapies; Tissue response

Indexed keywords

ADALIMUMAB; BACTERIAL ANTIGEN; CERTOLIZUMAB PEGOL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; MESALAZINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADAPTIVE IMMUNITY; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG SAFETY; ENDOTHELIUM CELL; ENTERITIS; ENVIRONMENTAL STRESS; GENETICS; GENOTYPE; HOMEOSTASIS; HOST PARASITE INTERACTION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REACTION;

BIOLOGICAL THERAPY; CONGRESSES; HOMEOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; SIGNAL TRANSDUCTION;

EID: 34548156973     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20127     Document Type: Conference Paper

References (165)

1. Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun. 2005;6:637-645.
2. Daly MJ, Rioux JD. New approaches to gene hunting in IBD. Inflamm Bowel Dis. 2004;10:312-317.
3. Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis. 2005;11:56-61.
4. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on CD risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393-2404.
5. Meier CB, Hegazi RA, Aisenberg J, et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 2005;11:965-971.
6. Kufer TA, Kremmer E, Banks DJ, Philpott DI. Role for erbin in bacterial activation of Nod2. Infect Immun. 2006;74:3115-3124.
7. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A. 2005;102:18129-18134.
8. Angelberger S, Schwab M, Dejaco C, et al. Association between NOD2/CARD15 gene variants and response to antibiotics in perianal fistulizing Crohn's disease. Inflamm Bowel Dis. 2006;12(Suppl 2):S17.
9. Brenmoehl J, Rogler G, Hahn J, et al. NOD2/CARD15 mutation associate with transplant-related mortality and GvHD in HLA-identical sibling transplants: detailed analysis of single SNPs in 209 recipient/donor pairs. Inflamm Bowel Dis. 2006;12(Suppl 2):S19.
10. Reinhard C, Rioux JD. Role of the IBD5 susceptibility locus in the inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:227-238.
11. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut. 2003;52:1133-1139.
12. Noble CL, Nimmo ER, Drummond H, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology. 2005;129:1854-1864.
13. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol. 2006;12:3628-3635.
14. Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003;62:527-535.
15. Ho GT, Soranzo N, Nimmo ER, et al. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet. 2006;15:797-805.
16. Yap LM, Lottaz D, Amhad T, et al. Polymorphisms in the MEP1A gene: a role in IBD? Inflamm Bowel Dis. 2006;12(Suppl 2):S19.
17. Amott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 2004;5:417-425.
18. Friedrichs F, Brescianini S, Annese V, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet. 2006;119:305-311.
19. Barnetche T, Gourraud PA, Cambon-Thomsen A. Strategies in analysis of the genetic component of multifactorial diseases; biostatistical aspects. Transpl Immunol. 2005;14:255-266.
20. Lay C, Rigottier-Gois L, Holmstrom K, et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol. 2005;71:4153-4155.
21. Seksik P, Sokol H, Lepage P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(Suppl 3):11-18.
22. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:106-111.
23. Seksik P, Lepage P, de la Cochetiere MF, et al. Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA. J Clin Microbiol. 2005;43:4654-4658.
24. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355-1359.
25. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol. 2001;1:69-75.
26. Adlerberth I, Carlsson B, de Man P, et al. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospital-delivered infants. Acta Paediatr Scand. 1991;80:602-610.
27. Adlerberth I, Jalil F, Carlsson B, et al. High turnover rate of Escherichia coli strains in the intestinal flora of infants in Pakistan. Epidemiol Infect. 1998;121:587-598.
28. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975-980.
29. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
30. Elliott DE, Li J, Blum A, et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G385-G391.
31. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128:825-832.
32. Sartor RB. Microbial and dietary factors in the pathogenesis of chronic, immune-mediated intestinal inflammation. Adv Exp Med Biol. 2006;579:35-54.
33. Sartor RB. Role of commensal enteric bacteria in the pathogenesis of immune-mediated intestinal inflammation: lessons from animal models and implications for translational research. J Pediatr Gastroenterol Nutr. 2005;40(Suppl 1):S30-31.
34. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891-906.
35. Bibiloni R, Mangold M, Madsen KL, et al. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol. 2006;55:1141-1149.
36. McBurney W, Mangold M, Munro K, et al. PCR/DGGE and 16S rRNA gene library analysis of the colonic microbiota of HLA-B27/beta2-microglobulin transgenic rats. Lett Appl Microbiol. 2006;42:165-171.
37. Walter J, Mangold M, Tannock GW. Construction, analysis, and beta-glucanase screening of a bacterial artificial chromosome library from the large-bowel microbiota of mice. Appl Environ Microbiol. 2005;71:2347-2354.
38. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol. 2004;41:1099-1108
39. Werts C, Girardin SE, Philpott DJ. TIR, CARD and PYRIN: three domains for an antimicrobial triad. Cell Death Differ. 2006;13:798-815.
40. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509-5512.
41. Ott SJ, Musfeldt M, Smalla K, et al. Alteration of composition and diversity of the mucosa-associated fungal microflora in patients with IBD. Inflamm Bowel Dis. 2006;12(Suppl 2):S20.
42. Franchi L, Özören N, Body-Malapel M, et al. Cytosolic recognition of intracellular bacteria by ASC and Ipaf overcomes endotoxin tolerance through induction of potent IL-1 secretion. Inflamm Bowel Dis. 2006;12(Suppl 2):S21.
43. Inoue T, Boyle DL, Corr M, et al. Mitogen-activated protein kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci U S A. 2006;103:5484-5489.
44. Firestein GS. Inhibiting inflammation in rheumatoid arthritis. N Engl J Med. 2006;354:80-82.
45. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:325-334.
46. Jump RL, Levine AD. Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:462-478.
47. Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn's. Gut. 2002;50:148-149.
48. Chen M, Wang YH, Wang Y, et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science. 2006;311:1160-1164.
49. Niess JH, Reinecker HC. Dendritic cells: the commanders-in-chief of mucosal immune defenses. Curr Opin Gastroenterol. 2006;22:354-360.
50. Salazar-Gonzalez RM, Niess JH, Zammit DJ, et al. CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches. Immunity. 2006;24:623-632.
51. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254-258.
52. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256-271.
53. Fahlen L, Read S, Gorelik L, et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2005;201:737-746.
54. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003;170:3939-3943.
55. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol. 2005;175:6900-6908.
56. Verstege MI, ten Kate FJW, van Vlijmen JR, et al. Dendritic cell populations in human mesenteric lymph nodes. Inflamm Bowel Dis. 2006;12(Suppl 2):S21.
57. Iliev ID, Rimoldi M, Rescigno M. Epithelial cells-dendritic cells crosstalk regulates the development of regulatory T cells in the gut. Inflamm Bowel Dis. 2006;12(Suppl 2):S22.
58. Fiocchi C, Ina K, Danese S, et al. Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases. Adv Exp Med Biol. 2006;579:168-176.
59. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073.
60. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229-241.
61. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 2005;26:447-454.
62. Lippert E, Falk W, Bataille F, et al. Soluble galectin-3 is a strong, colonic epithelial-cell derived, lamina propria fibroblast-stimulating factor. Gut. 2007;56:43-51.
63. Bataille F, Klebl F, Rummele P, et al. Morphological characterisation of Crohn's disease fistulae. Gut. 2004;53:1314-1321.
64. Shkoda A, Ruiz PA, Kim SC, et al. Intestinal epithelial cell signaling and host-derived negative regulators under chronic inflammation. Inflamm Bowel Dis. 2006;12(Suppl 2):S23.
65. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis. 2004;10:55-60.
66. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol. 2000;279:G653-G659.
67. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol. 1999;277:C1-C19.
68. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts II. Intestinal subepithelial myofibroblasts. Am J Physiol. 1999;277:C183-C201.
69. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-β isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-C182.
70. Wells RG. Fibrogenesis. V. TGF-β signaling pathways. Am J Physiol Gastroinest Liver Physiol. 2000;279:G845-G850.
71. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425:577-584.
72. Wengrower D, Zanninelli G, Pappo O, et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-β1. Inflamm Bowel Dis. 2004;10:536-545.
73. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:47-64.
74. Zanninelli G, Vetuschi A, Sferra R, et al. Smad3 knock-out mice as a useful model to study intestinal fibrogenesis. World J Gastroenterol. 2006;12:1211-1218.
75. Latella G, Zanninelli G, Vetuschi A, et al. Targeted disruption of TGF-β/Smad3 signaling confers resistance to intestinal fibrosis. Inflamm Bowel Dis. 2006;12(Suppl 2):S22.
76. Di Sabatino A, Bukley M, Pickard KM, et al. Transforming growth factor-β signaling and matrix metalloproteinase pattern in intestinal strictures in Crohn's disease. Inflamm Bowel Dis. 2006;12(Suppl 2):S22.
77. Michaylira CZ, Simmons JG, Ramocki NM, et al. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. Am J Physiol Gastrointest Liver Physiol. 2006;291:G472-481.
78. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005;280:36099-36109.
79. Theiss AL, Fuller CR, Simmons JG, et al. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology. 2005;129:204-219.
80. Fruchtman S, Simmons JG, Michaylira CZ, et al. Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. Am J Physiol Gastrointest Liver Physiol. 2005;289:G342-350.
81. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005;11:304-313.
82. Collins SM. Stress and the gastrointestinal tract. IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am J Physiol. 2001;280:G315-G318.
83. Ghia JE, Blennerhassett P, Ondiveeran HK, et al. The vagus nerve: a tonic inhibitory influence in a murine model of IBD. Inflamm Bowel Dis. 2006;12(Suppl 2):S22.
84. Ferrante M, De Hertogh G, Hlavaty T, et al. Myenteric plexitis in unaffected ileal resection margins predicts severe and early postoperative Crohn's disease recurrence. Inflamm Bowel Dis. 2006;12(Suppl 2):S29.
85. Doganci A, Neurath MF, Finotto S. Mucosal immunoregulation: transcription factors as possible therapeutic targets. Curr Drug Targets Inflamm Allergy. 2005;4:565-575.
86. Lowenberg M, Peppelenbosch MP, Hommes DW. Therapeutic modulation of signal transduction pathways. Inflamm Bowel Dis. 2004;10(Suppl 1):S52-57.
87. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 2005;54:1182-1193.
88. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003;3:371-382.
89. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;280-288.
90. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
91. Rakesh K, Agrawal DK. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol. 2005;70:649-657.
92. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Current Opinin Cell Biology. 2005;4:1296-1302.
93. Guertin DA, Guntur KV, Bell GW, et al. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol. 2006;16:958-970.
94. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.
95. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168.
96. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
97. Kelly D, Campbell JL, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and relA. Nat Immunol. 2004;5:104-112.
98. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341-1349.
99. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006;24(Suppl 1):2-9.
100. Monteleone G, Croft NM, Kumberova A, et al. Blocking smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
101. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-β-mediated negative regulation of gut inflammation. Trends Immunol. 2004;25:513-517.
102. Monteleone G. Del Vecchio Blanco G, Monteleone I, et al. Changes in Smad ubiquitination/acetylation status explain the failure of TGFB to negatively regulate ongoing human gut inflammation. Gastroenterology. 2005;129:1420-1429.
103. Hue S, Maloy K, McKensie B, et al. IL-23 and not IL-12 is essential for the development of IBD. Inflamm Bowel Dis. 2006;12(Suppl 2):S25.
104. Atreya I, Diall A, Poppe D, et al. 6-thio-GTP derivates: a novel class of immunosuppressive drugs? Inflamm Bowel Dis. 2006;12(Suppl 2):S25.
105. Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2006;9:201-210.
106. Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol. 2006;22:30-43.
107. Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis. 2005;37:973-979.
108. Hommes D, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top-down versus step-up strategies. Gastroenterology. 2005;128(Suppl 2):A577.
109. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2006;3:220-228.
110. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1017-1024.
111. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics. 2004;5:479-486.
112. Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis. 2004;10(Suppl 1):S38-43.
113. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
114. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805.
115. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
116. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818
117. van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology. 2006;45:1187-1193.
118. Griffith LM, Pavletic SZ, Tyndall A, et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases - a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant. 2006;12:688-690.
119. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35:869-879.
120. Hawkey CJ. Stem cell transplantation for Crohn's disease. Best Pract Res Clin Haematol. 2004;17:317-325.
121. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005;128:552-563.
122. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host-disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.
123. Korzenik JR, Dieckgraefe BK. Is Crohn's disease and immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci. 2000;45:1121-1129.
124. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colon-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther. 2005;21:391-400.
125. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005;352:2193-2201.
126. Kamm WJ, Lichtenstein GR, Sandborn MA, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-side and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III study. Gastroenterology. 2006;130(Suppl 2):A484.
127. Braat H, Rottiers P, Huyghebaert N, et al. IL-10 producing Lactococcus lactis for the treatment of Crohn's disease. Inflamm Bowel Dis. 2006;12(Suppl 2):S26.
128. Sturm A, Paclik D, Wiedenmann B, et al. Galectin-2, a potent modulator of T cell apoptosis, profoundly downregulates intestinal inflammation and improves disease activity in an experimental model of murine colitis. Inflamm Bowel Dis. 2006;12(Suppl 2):S28.
129. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
130. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(Suppl 1):i16-35.
131. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
132. Baumgart DC, Hommes DW, Reinisch W, et al. The phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids. Gut. 2005;54(Suppl VII):A57.
133. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608
134. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
135. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-39.
136. Rubin DT, Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol. 2006;9:211-220.
137. Boland CR, Luciani MG, Gasche C, Goel A. Infection, inflammation and GI cancer. "Recent Advances in Basic Science." Gut. 2005;54:1321-1331.
138. Rabinovitch PS, Dziadon S, Brentnall TA, et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 1999;59:5148-5153.
139. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000;60:4864-4868.
140. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573-3577.
141. Risques RA, Rabinovitch PS, Brentnall TA. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr Opin Gastroenterol. 2006;22:382-390.
142. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005;100:1354-1356.
143. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
144. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res. 2005;65:3993-3997.
145. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol. 2006;12:3657-3667.
146. Egan LJ, Derijks LJ, Hommes DW. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:21-28.
147. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002;123:106-111.
148. Willot S, Vermeire S, Ohresser M, et al. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics. 2006;16:37-42.
149. Will M, Nikolaus S, Freitag S, et al. Placebo response in the therapy of Crohn's disease: a comprehensive analysis of primary data from 733 patients from 13 randomized, controlled trials. Inflamm Bowel Dis. 2006;12(Suppl 2):S29.
150. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005;143:895-904.
151. Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr Opin Pharmacol. 2006;6:401-407.
152. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006;203:541-552.
153. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
154. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
155. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
156. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov. 2006;5:197-209.
157. Dubinsky MC, Taylor K, Targan SR, Rotter JI. Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol. 2006;12:3645-3650.
158. Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv Exp Med Biol. 2006;579:209-218.
159. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
160. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
161. Devlin SM, Ippoliti A, Yang H, et al. NOD2 variants are significantly associated with sero-reactivity to microbial antigens in Crohn's disease. Gastroenterology. 2006;130(Suppl 3):A64.
162. Mei L, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006;130:1078-1085.
163. Rotter J, Taylor KD, Yang H, et al. TLR5 polymorphisms are associated with OmpC and CBR1 expression and with severity of Crohn's disease in Ashkenazi jews. Gastroenterology. 2006;130(Suppl 3):A53.
164. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028.
165. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367.